Is DexCom Stock a Good Investment?
DexCom Investment Advice | DXCM |
- Examine DexCom's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research DexCom's leadership team and their track record. Good management can help DexCom navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact DexCom's business and its evolving consumer preferences.
- Compare DexCom's performance and market position to its competitors. Analyze how DexCom is positioned in terms of product offerings, innovation, and market share.
- Check if DexCom pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about DexCom's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in DexCom Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if DexCom Inc is a good investment.
Sell | Buy |
Strong Buy
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine DexCom Stock
Researching DexCom's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.25. DexCom Inc had not issued any dividends in recent years. The entity had 4:1 split on the 13th of June 2022.
To determine if DexCom is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding DexCom's research are outlined below:
| DexCom Inc is unlikely to experience financial distress in the next 2 years | |
| DexCom Inc has a strong financial position based on the latest SEC filings | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from insidermonkey.com: Why DexCom, Inc. Is Skyrocketing |
DexCom Quarterly Liabilities And Stockholders Equity |
|
DexCom uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in DexCom Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DexCom's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact DexCom's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises DexCom's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-04-29 | 2021-03-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2019-07-31 | 2019-06-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2016-04-27 | 2016-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2015-04-29 | 2015-03-31 | -0.03 | -0.04 | -0.01 | 33 | ||
2014-11-06 | 2014-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2014-08-06 | 2014-06-30 | -0.03 | -0.02 | 0.01 | 33 | ||
2014-02-20 | 2013-12-31 | -0.02 | -0.01 | 0.01 | 50 |
DexCom Target Price Consensus
DexCom target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. DexCom's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 25 | Strong Buy |
Most DexCom analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand DexCom stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of DexCom Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDexCom Target Price Projection
DexCom's current and average target prices are 84.38 and 96.26, respectively. The current price of DexCom is the price at which DexCom Inc is currently trading. On the other hand, DexCom's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On DexCom Target Price
DexCom Analyst Ratings
DexCom's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about DexCom stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of DexCom's financials, market performance, and future outlook by experienced professionals. DexCom's historical ratings below, therefore, can serve as a valuable tool for investors.Know DexCom's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DexCom is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DexCom Inc backward and forwards among themselves. DexCom's institutional investor refers to the entity that pools money to purchase DexCom's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wellington Management Company Llp | 2024-09-30 | 5.7 M | Jpmorgan Chase & Co | 2024-09-30 | 5.6 M | Amvescap Plc. | 2024-09-30 | 5.5 M | Norges Bank | 2024-06-30 | 5.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.3 M | Bank Of New York Mellon Corp | 2024-09-30 | 4.8 M | American Century Companies Inc | 2024-09-30 | 4 M | Amundi | 2024-09-30 | 3.8 M | Northern Trust Corp | 2024-09-30 | 3.4 M | Vanguard Group Inc | 2024-09-30 | 47.4 M | Blackrock Inc | 2024-09-30 | 35 M |
DexCom's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 33.14 B.Market Cap |
|
DexCom's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.08 | 0.08 | |
| Return On Capital Employed | 0.11 | 0.12 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | 0.24 | 0.25 |
Determining DexCom's profitability involves analyzing its financial statements and using various financial metrics to determine if DexCom is a good buy. For example, gross profit margin measures DexCom's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of DexCom's profitability and make more informed investment decisions.
DexCom's Earnings Breakdown by Geography
Evaluate DexCom's management efficiency
DexCom Inc has return on total asset (ROA) of 0.0606 % which means that it generated a profit of $0.0606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3206 %, meaning that it created $0.3206 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of January 2025, Return On Tangible Assets is likely to grow to 0.08. Also, Return On Capital Employed is likely to grow to 0.12. At this time, DexCom's Net Tangible Assets are very stable compared to the past year. As of the 17th of January 2025, Intangible Assets is likely to grow to about 162.4 M, while Intangibles To Total Assets are likely to drop 0.03.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.82 | 5.06 | |
| Tangible Book Value Per Share | 4.45 | 4.67 | |
| Enterprise Value Over EBITDA | 49.02 | 51.47 | |
| Price Book Value Ratio | 20.84 | 21.88 | |
| Enterprise Value Multiple | 49.02 | 51.47 | |
| Price Fair Value | 20.84 | 21.88 | |
| Enterprise Value | 220.9 M | 231.9 M |
DexCom showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.173 |
Basic technical analysis of DexCom Stock
As of the 17th of January 2025, DexCom shows the Downside Deviation of 1.71, coefficient of variation of 666.02, and Mean Deviation of 1.66. DexCom Inc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm DexCom Inc jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if DexCom Inc is priced favorably, providing market reflects its regular price of 84.38 per share. Given that DexCom has jensen alpha of 0.3228, we urge you to verify DexCom Inc's prevailing market performance to make sure the company can sustain itself at a future point.DexCom's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DexCom insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DexCom's Outstanding Corporate Bonds
DexCom issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DexCom Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DexCom bonds can be classified according to their maturity, which is the date when DexCom Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| International Game Technology Corp BondUS460599AD57 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand DexCom's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing DexCom's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1318 | |||
| Market Risk Adjusted Performance | 179.35 | |||
| Mean Deviation | 1.66 | |||
| Semi Deviation | 1.45 | |||
| Downside Deviation | 1.71 | |||
| Coefficient Of Variation | 666.02 | |||
| Standard Deviation | 2.22 | |||
| Variance | 4.91 | |||
| Information Ratio | 0.1472 | |||
| Jensen Alpha | 0.3228 | |||
| Total Risk Alpha | 0.332 | |||
| Sortino Ratio | 0.1913 | |||
| Treynor Ratio | 179.34 | |||
| Maximum Drawdown | 10.13 | |||
| Value At Risk | (2.79) | |||
| Potential Upside | 5.52 | |||
| Downside Variance | 2.91 | |||
| Semi Variance | 2.09 | |||
| Expected Short fall | (1.92) | |||
| Skewness | 0.9029 | |||
| Kurtosis | 0.8256 |
| Risk Adjusted Performance | 0.1318 | |||
| Market Risk Adjusted Performance | 179.35 | |||
| Mean Deviation | 1.66 | |||
| Semi Deviation | 1.45 | |||
| Downside Deviation | 1.71 | |||
| Coefficient Of Variation | 666.02 | |||
| Standard Deviation | 2.22 | |||
| Variance | 4.91 | |||
| Information Ratio | 0.1472 | |||
| Jensen Alpha | 0.3228 | |||
| Total Risk Alpha | 0.332 | |||
| Sortino Ratio | 0.1913 | |||
| Treynor Ratio | 179.34 | |||
| Maximum Drawdown | 10.13 | |||
| Value At Risk | (2.79) | |||
| Potential Upside | 5.52 | |||
| Downside Variance | 2.91 | |||
| Semi Variance | 2.09 | |||
| Expected Short fall | (1.92) | |||
| Skewness | 0.9029 | |||
| Kurtosis | 0.8256 |
Consider DexCom's intraday indicators
DexCom intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of DexCom stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 142393.0 | |||
| Daily Balance Of Power | (0.19) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 85.11 | |||
| Day Typical Price | 84.87 | |||
| Price Action Indicator | (0.96) | |||
| Period Momentum Indicator | (0.46) |
DexCom Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 6th of December 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 29th of May 2024 Other Reports | ViewVerify |
DexCom Stock media impact
Far too much social signal, news, headlines, and media speculation about DexCom that are available to investors today. That information is available publicly through DexCom media outlets and privately through word of mouth or via DexCom internal channels. However, regardless of the origin, that massive amount of DexCom data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of DexCom news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of DexCom relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to DexCom's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive DexCom alpha.
DexCom Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards DexCom can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
DexCom Inc Historical Investor Sentiment
Investor biases related to DexCom's public news can be used to forecast risks associated with an investment in DexCom. The trend in average sentiment can be used to explain how an investor holding DexCom can time the market purely based on public headlines and social activities around DexCom Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
DexCom's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for DexCom and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average DexCom news discussions. The higher the estimate score, the more favorable the investor's outlook on DexCom.
DexCom Maximum Pain Price Across March 21st 2025 Option Contracts
DexCom's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of DexCom close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of DexCom's options.
DexCom Corporate Management
| Shelly Selvaraj | Senior Officer | Profile | |
| Leverne Marsh | Executive Marketing | Profile | |
| Matthew Dolan | Corporate Strategy | Profile | |
| Teri Lawver | Executive Officer | Profile | |
| Donald Abbey | Quality Services | Profile | |
| Jereme Sylvain | CFO VP | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share | Quarterly Revenue Growth 0.02 | Return On Assets |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between DexCom's value and its price, as these two are different measures arrived at by various means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.